25.09.2019 • NewsPeopleHenkelMichael Nilles

Henkel Appoints Michael Nilles as Chief Digital & Information Officer

Henkel has appointed Michael Nilles as chief digital & information officer...
Henkel has appointed Michael Nilles as chief digital & information officer (CDIO), effective Oct. 1, 2019. Source: Henkel

Henkel has appointed Michael Nilles as chief digital & information officer (CDIO), effective Oct. 1, 2019. He will succeed Rahmyn Kress, who will become head of Henkel X Ventures.

Prior to joining Henkel, Nilles (46) was chief digital officer and chief information officer of the Schindler Group and CEO of Schindler Digital Business. He began his career in 1996 with SAP China and subsequently held various international positions in the field of digital business transformation, including as CIO Americas and Group CIO of Bosch Rexroth. He holds a degree in Business Informatics from the University of Cologne and is a graduate of the Kellogg School of Management in Evanston, Illinois,USA.

In his new role, Nilles will be responsible for the combined activities in Integrated Business Solutions (IBS) and digital technologies. Joachim Jäckle, currently responsible for IBS at Henkel, will retire after 28 years with Henkel by the end of 2019.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.